Patent ID: 8747897

Claim:
An oral osmotic pharmaceutical dosage form of treprostinil, comprising an osmotically active drug core surrounded by a semi-permeable membrane, wherein the osmotically active drug core comprises A) at least one release enhancing agent selected from a group consisting of wicking agents, complexing agents, and micelle-forming agents, wherein i) the wicking agents are selected from the group consisting of high HLB surfactants, ionic surfactants, and non-swelling hydrophilic polymers, ii) the complexing agents are selected from the group consisting of polyvinyl pyrrolidone, cyclodextrins, and non-ionic surface active agents, and iii) the micelle-forming agents are selected from the group consisting of poly(ethylene oxide) modified sorbitan monoesters, fatty acid sorbitan esters, sodium lauryl sulfate, and sodium docusate, and B) treprostinil as treprostinil diethanolamine, and wherein the semi-permeable membrane includes at least one opening suitable for providing for the osmotic delivery of the treprostinil from the osmotically active drug core.